Julie Rubinstein sold $1.0M of ADPT
President and COO at Adaptive Biotechnologies Corp. 35,643 shares at an average of $28.46, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +20RolePresident
- +25Trade size$1.0M at market
- 0Share of holdings soldSold 9.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001780664-26-000035, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -6,081 | $27.57 | $168k | 383,602 | 7 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -5,800 | $28.56 | $166k | 377,802 | 7 d ago |
| Oct 2, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -11,881 | $28.13 | $334k | 377,802 | 7 d ago |
| Oct 5, 2026 | MOption exercise Common Stock10b5-1 | +11,881 | $12.14 | $144k | 389,683 | 7 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -6,699 | $28.82 | $193k | 382,984 | 7 d ago |
| Oct 5, 2026 | SOpen-market sale Common Stock10b5-1 | -5,182 | $29.67 | $154k | 377,802 | 7 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 367,896 | 7 d ago |
| Oct 2, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 356,015 | 7 d ago |
| Oct 5, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,881 | $0.00 | $0 | 344,134 | 7 d ago |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| 22Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 0Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $77k 4,394 shares | -1% | |
| 30Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $1.8M 113,890 shares | -26% | |
| 55Moderate | Adaptive Biotechnologies Corp | Robert Hershberg director | $367k 22,968 shares | -33% | |
| 7Weak | Adaptive Biotechnologies Corp | Sharon Benzeno Chief Commercial Ofc Imm Med | $212k 12,604 shares | -4% | |
| 30Weak | Adaptive Biotechnologies Corp | Harlan S Robins Chief Scientific Officer | $673k 37,212 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.